Literature DB >> 14598626

Early Start: an obstetric clinic-based, perinatal substance abuse intervention program.

M A Armstrong1, L Lieberman, D M Carpenter, V M Gonzales, M S Usatin, L Newman, G J Escobar.   

Abstract

Maternal substance abuse is a serious problem with significant adverse effects to mothers, fetuses, and children. The Early Start Program provides pregnant women in a managed care organization with screening and early identification of substance abuse problems, early intervention, ongoing counseling, and case management by a licensed clinical social worker located in the prenatal clinic, where she is an integral part of the prenatal team. We describe the development of the Early Start Program, its administrative history, and how it has interfaced with clinicians and administrators. We also highlight two important program characteristics: the partnership with a perinatal health services research unit and the degree to which the program could be "exported" to other managed care settings.

Entities:  

Mesh:

Year:  2001        PMID: 14598626     DOI: 10.1097/00019514-200109020-00004

Source DB:  PubMed          Journal:  Qual Manag Health Care        ISSN: 1063-8628            Impact factor:   0.926


  10 in total

1.  Gender differences in provider's use of a standardized screening tool for prenatal substance use.

Authors:  Carrie Oser; Elizabeth Biebel; Melissa Harris; Elisa Klein; Carl Leukefeld
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

2.  Correlates of Pregnant Women's Participation in a Substance Use Assessment and Counseling Intervention Integrated into Prenatal Care.

Authors:  Kelly C Young-Wolff; Lue-Yen Tucker; Mary Anne Armstrong; Amy Conway; Constance Weisner; Nancy Goler
Journal:  Matern Child Health J       Date:  2020-04

3.  Validity of Self-reported Cannabis Use Among Pregnant Females in Northern California.

Authors:  Kelly C Young-Wolff; Varada Sarovar; Lue-Yen Tucker; Nancy Goler; Amy Conway; Constance Weisner; Mary Anne Armstrong; Stacey Alexeeff
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

4.  Mortality risk associated with perinatal drug and alcohol use in California.

Authors:  Ellen L Wolfe; Thomas Davis; Joseph Guydish; Kevin L Delucchi
Journal:  J Perinatol       Date:  2005-02       Impact factor: 2.521

5.  Vision, Research, Innovation and Influence: Early Start's 15-Year Journey from Pilot Project to Regional Program.

Authors:  Leslie Lieberman; Cosette Taillac; Nancy Goler
Journal:  Perm J       Date:  2005

6.  Pregnancy outcomes by pregnancy intention in a managed care setting.

Authors:  Debbie Postlethwaite; Mary Anne Armstrong; Yun-Yi Hung; Ruth Shaber
Journal:  Matern Child Health J       Date:  2009-01-19

7.  Motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice: a randomized trial for treatment of hazardous substance use in pregnancy and after delivery.

Authors:  Kimberly A Yonkers; Ariadna Forray; Heather B Howell; Nathan Gotman; Trace Kershaw; Bruce J Rounsaville; Kathleen M Carroll
Journal:  Gen Hosp Psychiatry       Date:  2012-07-12       Impact factor: 3.238

8.  Using drink size to talk about drinking during pregnancy: a randomized clinical trial of Early Start Plus.

Authors:  Mary Anne Armstrong; Lee Ann Kaskutas; Jane Witbrodt; Cosette J Taillac; Yun-Yi Hung; Veronica M Osejo; Gabriel J Escobar
Journal:  Soc Work Health Care       Date:  2009

9.  Early start: an integrated model of substance abuse intervention for pregnant women.

Authors:  Cosette Taillac; Nancy Goler; Mary Anne Armstrong; Kathleen Haley; Veronica Osejo
Journal:  Perm J       Date:  2007

10.  The Kaiser Permanente Northern California research program on genes, environment, and health (RPGEH) pregnancy cohort: study design, methodology and baseline characteristics.

Authors:  M M Hedderson; A Ferrara; L A Avalos; S K Van den Eeden; E P Gunderson; D K Li; A Altschuler; S Woo; S Rowell; V Choudhary; F Xu; T Flanagan; C Schaefer; L A Croen
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-29       Impact factor: 3.007

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.